Costs of management of acute respiratory infections in older adults: A systematic review and meta-analysis.

Shanshan Zhang, Pia Wahi-Singh, Bhanu Wahi-Singh, Alison Chisholm, Polly Keeling, Harish Nair, RESCEU Investigators
Author Information
  1. Shanshan Zhang: Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.
  2. Pia Wahi-Singh: Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.
  3. Bhanu Wahi-Singh: Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.
  4. Alison Chisholm: Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.
  5. Polly Keeling: Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.
  6. Harish Nair: Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.

Abstract

Background: Acute respiratory infections (ARIs) accounted for an estimated 3.9 million deaths worldwide in 2015, of which 56% occurred in adults aged 60 years or older. We aimed to identify the cost of ARI management in older adults (≥50 years) in order to develop an evidence base to assist decision-making for resource allocation and inform clinical practice.
Methods: We searched 8 electronic databases including Global Health, Medline and EMBASE for studies published between January 1, 2000 and December 31, 2021. Total management costs per patient per ARI episode were extracted and meta-analysis was conducted by World Health Organization (WHO) region and World Bank income level. All costs were converted and inflated to Euros (€) (2021 average exchange rate). The quality of included studies and the potential risk of bias were evaluated.
Results: A total of 42 publications were identified for inclusion, reporting cost data for 8 082 752 ARI episodes in older adults across 20 countries from 2001 to 2021. The majority (86%) of studies involved high-income countries based in Europe, North America and Western Pacific. The mean cost per episode was €17 803.9 for inpatient management and €128.9 for outpatient management. Compared with costs reported for patients aged <65 years, inpatient costs were €154.1, €7 018.8 and €8 295.6 higher for patients aged 65-74 years, 75-84 years and over 85 years. ARI management of at-risk patients with comorbid conditions and patients requiring higher level of care, incurred substantially higher costs for hospitalization: €735.9 and €1317.3 respectively.
Conclusions: ARIs impose a substantial economic burden on health systems, governments, patients and societies. This study identified high ARI management costs in older adults, reinforcing calls for investment by global health players to quantify and address the scale of the challenge. There are large gaps in data availability from low-income countries, especially from South East Asia and Africa regions.

References

  1. Sci Rep. 2020 Jul 21;10(1):12106 [PMID: 32694533]
  2. PLoS One. 2013 Aug 06;8(8):e71375 [PMID: 23940743]
  3. Int J Infect Dis. 2015 Nov;40:102-7 [PMID: 25813554]
  4. Cochrane Database Syst Rev. 2015 May 27;(5):CD007988 [PMID: 26014500]
  5. PLoS One. 2020 Jun 11;15(6):e0234235 [PMID: 32525898]
  6. BMC Infect Dis. 2013 May 04;13:202 [PMID: 23641904]
  7. BMC Public Health. 2020 Sep 29;20(1):1464 [PMID: 32993588]
  8. Vaccines (Basel). 2018 Aug 31;6(3): [PMID: 30200286]
  9. J Infect Dis. 2020 Aug 17;222(6):962-966 [PMID: 32300806]
  10. J Am Geriatr Soc. 2004 Jan;52(1):31-8 [PMID: 14687312]
  11. J Am Med Dir Assoc. 2017 May 1;18(5):453.e7-453.e12 [PMID: 28433120]
  12. Turk Thorac J. 2015 Jul;16(3):107-113 [PMID: 29404087]
  13. Clin Ther. 2015 Jul 1;37(7):1466-1476.e1 [PMID: 26001310]
  14. J Am Med Dir Assoc. 2003 Mar-Apr;4(2):81-9 [PMID: 12807579]
  15. Influenza Other Respir Viruses. 2022 Jan;16(1):151-158 [PMID: 34605182]
  16. BMC Infect Dis. 2014 Sep 05;14:485 [PMID: 25192701]
  17. J Korean Med Sci. 2013 Jun;28(6):888-95 [PMID: 23772154]
  18. PLoS One. 2020 Aug 6;15(8):e0236472 [PMID: 32760071]
  19. Hum Vaccin Immunother. 2017 Jul 3;13(7):1673-1680 [PMID: 28281915]
  20. Appl Health Econ Health Policy. 2013 Jun;11(3):251-8 [PMID: 23605251]
  21. Am Health Drug Benefits. 2013 Sep;6(8):494-503 [PMID: 24991378]
  22. J Am Geriatr Soc. 2012 Nov;60(11):2137-43 [PMID: 23110409]
  23. J Am Geriatr Soc. 2008 Jun;56(6):969-75 [PMID: 18410319]
  24. Eur Respir J. 2004 Apr;23(4):610-6 [PMID: 15083763]
  25. Clin Ther. 2008 Feb;30(2):358-71 [PMID: 18343274]
  26. Pneumonia (Nathan). 2017 Dec 05;9:19 [PMID: 29226070]
  27. Eur J Public Health. 2001 Dec;11(4):362-4 [PMID: 11766474]
  28. Thorax. 2008 Aug;63(8):690-7 [PMID: 18250183]
  29. Pharmacoecon Open. 2021 Jun;5(2):275-284 [PMID: 33225412]
  30. Chest. 2012 Oct;142(4):973-981 [PMID: 22406959]
  31. BMC Public Health. 2015 Apr 07;15:330 [PMID: 25880910]
  32. Clin Interv Aging. 2020 Aug 27;15:1513-1519 [PMID: 32943854]
  33. BMC Health Serv Res. 2016 May 13;16:182 [PMID: 27177430]
  34. BMC Geriatr. 2018 Apr 16;18(1):92 [PMID: 29661135]
  35. Vaccine. 2016 Apr 27;34(19):2275-80 [PMID: 26979138]
  36. BMC Public Health. 2019 Aug 13;19(1):1090 [PMID: 31409319]
  37. Am J Respir Crit Care Med. 2002 Mar 15;165(6):766-72 [PMID: 11897642]
  38. Syst Rev. 2015 Jan 01;4:1 [PMID: 25554246]
  39. J Am Geriatr Soc. 2021 Mar;69(3):696-703 [PMID: 33294986]
  40. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006602 [PMID: 23633336]
  41. J Glob Health. 2016 Jun;6(1):010408 [PMID: 27231544]
  42. BMC Infect Dis. 2016 Sep 02;16:466 [PMID: 27589847]
  43. Global Health. 2020 Oct 8;16(1):93 [PMID: 33032618]
  44. Turk Thorac J. 2019 Jul 30;20(4):216-223 [PMID: 31390327]
  45. Eur J Health Econ. 2011 Aug;12(4):319-29 [PMID: 20364288]
  46. Vaccine. 2015 Jun 22;33(28):3193-9 [PMID: 25981488]
  47. Crit Care. 2021 Jan 10;25(1):24 [PMID: 33423691]
  48. Infect Drug Resist. 2021 May 18;14:1845-1853 [PMID: 34040398]
  49. Cochrane Database Syst Rev. 2018 Oct 29;10:CD010257 [PMID: 30371937]
  50. Lancet Glob Health. 2017 Dec;5(12):e1176-e1177 [PMID: 29128252]
  51. BMC Pulm Med. 2021 Nov 3;21(1):345 [PMID: 34732194]
  52. Am J Med. 2003 Oct 1;115(5):343-51 [PMID: 14553868]

MeSH Term

Humans
Aged
Respiratory Tract Infections
Hospitalization
Poverty
Global Health
Europe

Word Cloud

Created with Highcharts 10.0.0managementyearscostsolderARIpatients9adultsagedcoststudies2021percountrieshigherrespiratoryinfectionsARIs38Health1episodemeta-analysisWorldlevelidentifieddatainpatienthealthBackground:Acuteaccountedestimatedmilliondeathsworldwide201556%occurred60aimedidentify≥50orderdevelopevidencebaseassistdecision-makingresourceallocationinformclinicalpracticeMethods:searchedelectronicdatabasesincludingGlobalMedlineEMBASEpublishedJanuary2000December31TotalpatientextractedconductedOrganizationWHOregionBankincomeconvertedinflatedEurosaverageexchangeratequalityincludedpotentialriskbiasevaluatedResults:total42publicationsinclusionreporting8 082 752episodesacross202001majority86%involvedhigh-incomebasedEuropeNorthAmericaWesternPacificmean€17 803€128outpatientComparedreported&lt65€154€7 018€8 295665-7475-8485at-riskcomorbidconditionsrequiringcareincurredsubstantiallyhospitalization:€735€1317respectivelyConclusions:imposesubstantialeconomicburdensystemsgovernmentssocietiesstudyhighreinforcingcallsinvestmentglobalplayersquantifyaddressscalechallengelargegapsavailabilitylow-incomeespeciallySouthEastAsiaAfricaregionsCostsacuteadults:systematicreview

Similar Articles

Cited By